Clinical Trials Browser

Interventional × HER2-negative Metastatic Breast Cancer × Breast × Clear all

NCT04720729 2025-06-22

MONDRIAN

Phase 2 Terminated

HER2-negative Metastatic Breast Cancer

NCT06533722 2025-06-10

Adaptive Therapy for Post-Second-Line Advanced Breast Cancer

Phase 2 Completed

HER2-negative Metastatic Breast Cancer

NCT05261269 2023-12-13

A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer

Phase 1 Completed

HER2-negative Metastatic Breast Cancer